Typically, tumor uptake of radiolabeled SSTR2 antagonists shows higher robustness against increasing peptide amounts, as tumor cells have a much higher binding capacity for antagonists compared to agonists 42, 59, 61. This evidence concerns the gene SSTR2 and neoplasm.